NASDAQ: CORT

Corcept Therapeutics (CORT) Stock Analysis & Forecast

Nov 13 close

$72.94−0.77 (−1.0%)

Gekko Brief

AI summaryNov 9 close

Corcept Therapeutics this week drew attention on multiple fronts following its Q3 2026 report on 3 November. Revenue reached $340.5 million, up 64% year-over-year, with Korlym/authorized generic contributing $249.1 million and newly launched Lifyorli adding $91.4 million. Net income rose to $126.8 million from $19.7 million a year earlier, and cash stood at $662 million. Commentary since has centered on valuation, with CORT trading at 7.9 times trailing revenue versus the S&P 500's 3.3 times, alongside a Moderate Buy consensus rating cited by MarketBeat.com. Separate filings noted insider stock sales by the president of oncology and a former president of Corcept Endocrinology under pre-arranged trading plans.

CORT closed at $75.03, up 3.1% on the day, with its close sitting between the 50-day average of $106.80 and the 200-day average of $75.94. The one-month return stands at -38.1% and the three-month return at -32.9%, while the six-month return is 46.5%. The GekkoIndex reads 73.6, placing the stock in the Buying zone, down 3.7 over five days. Price sits 25.2% below the Gekko Fair Value of $100.33.

The next earnings date falls on 23 February 2027, 105 days out and beyond a typical 20-trading-day holding window; the prior report produced a -1.5% reaction despite beating estimates, with four beats in the last eight quarters. No insider, Congress, or unusual options activity appears in their respective windows. Seasonality for this calendar point shows a 20-trading-day average return of 3% over five years, rising in three of them. Four analysts carry Buy ratings with a consensus target of $141, implying 87.9% consensus upside.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Corcept Therapeutics price vs fair value

$97.61$72.94Nov ’25May ’26Nov ’26
Close $72.94200-day averageGekko Fair Value $97.61

Corcept Therapeutics quick facts

Market cap
$7.98B
P/E ratio
55.4
Forward P/E
15.2
EPS, TTM
$1.33
Revenue, TTM
$963.6M
Profit margin
16.8%
Dividend yield
—
Beta
0.56
Volume
1.11M avg 1.30M
1-year return
−7.0%
Typical daily move
±6.4%
Typical 20-day move
±10.1%
50-day average
$103.70
200-day average
$76.50
Next earnings
Feb 23 after close
Shares outstanding
109.4M
52-week range
$28.66$126.38

Corcept Therapeutics swing-trade checklist

Corcept Therapeutics scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive1 mixed1 headwind

  • Trendmixed

    Averages disagree

    Close $72.94 sits between the 50-day ($103.70) and 200-day ($76.50) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    68.6, Accumulation

    Reading 68.6 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    25.3% below

    Price is 25.3% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 100 days

    Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −0.4% on average

    From this point in the calendar, the next 20 trading days averaged −0.4% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Corcept Therapeutics stock chart and price history

Corcept Therapeutics closed at $72.94 on Nov 13, 2026, −7.0% over the past year, inside a 52-week range of $28.66 to $126.38.

Close50-day average200-day averageVolume
Corcept Therapeutics share price, past year, with 50-day and 200-day moving averages and volume$40$60$80$100$120DecJan 2026FebMarAprMayJunJulAugSepOctNov72.94

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−35.7%
3 months
−37.7%
6 months
+29.4%
1 year
−7.0%
The full CORT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CORT in Gekko

Follow Corcept Therapeutics through every session

Put CORT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track CORT in GekkoFree for 7 days. No credit card required.

About Corcept Therapeutics

Corcept Therapeutics focuses on treatments for patients dealing with serious hormonal, cancer-related, and mental health conditions, marketing its products within the United States. Its main approved treatment is Korlym, a mifepristone tablet taken once each day, used to address elevated blood sugar linked to excess cortisol in adults facing endogenous Cushing's syndrome, especially those managing type 2 diabetes or impaired glucose tolerance who are not candidates for surgery or have not benefited from it.

Alongside this marketed treatment, Corcept continues research into new therapies. One candidate, relacorilant, is being tested as a standalone option for Cushing's syndrome and also paired with nab-paclitaxel, a combination that has finished Phase II study for ovarian cancer that has spread and is under review for other illnesses tied to elevated cortisol levels. Separate efforts target selective cortisol modulators meant for prostate cancer that resists standard hormone therapy and for weight gain linked to antipsychotic drugs, together with laboratory research into a gene expression assay tied to FKBP5.

Corcept Therapeutics shares trade on the NASDAQ under the ticker CORT.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
corcept.com

Corcept Therapeutics GekkoIndex: the smart money zone

Corcept Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 68.6, in the Accumulation zone, down 7.5 points over five sessions.

010068.6Accumulation

Down 7.5 points over five sessions, from the Buying zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying26−1.8%+3.6%+7.8%+6.5%
Accumulation (current zone)169+1.7%+4.4%+11.7%+19.3%
Neutral428+1.8%+2.3%+4.6%+16.9%
Distribution75−0.3%+2.9%+3.9%+21.8%
Selling4Too few readings yet

Average CORT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the CORT price, zone by zone.Track CORT in Gekko

Is Corcept Therapeutics stock overvalued? Gekko Fair Value

Corcept Therapeutics trades 25.3% below Gekko Fair Value of $97.61, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Corcept Therapeutics shares are worth, recalculated every trading day.

$97.61

Gekko Fair Value, Nov 14, 2026

25.3% Undervalued

At the end of Aug 2026 the price was 12.9% above the estimate.

Gekko Fair ValueShare price, month end
$98$73Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open CORT in Gekko

Corcept Therapeutics insider and Congress trading

No open-market insider purchases were filed for Corcept Therapeutics, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for CORT in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every CORT insider filing, plotted on the chart in Gekko.Open CORT in Gekko

Congress trades last 90 days

No trades in CORT were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for CORT, plotted on the chart in Gekko.Open CORT in Gekko

Buybacks

Corcept Therapeutics has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$5.75M
As a share of market cap
0.07%
Trailing four quarters
$59.50M

From company filings.

Corcept Therapeutics earnings: next date and track record

Corcept Therapeutics reports on Feb 23, 2027, after the close (100 days away), and beat the EPS estimate in 4 of its last 8 reports.

4 of 8reports beat the EPS estimate
±6.2%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

−2.3%Feb ’25−2.8%May ’25−1.3%Jul ’25+3.3%Nov ’25+2.5%Feb ’26+10.4%Apr ’26+25.6%Jul ’26−1.5%Nov ’26

Last earnings call, Nov 3, 2026 AI summary

What they said
Corcept reported Q3 2026 revenue of $340.5 million, up 64% year-over-year, with Korlym/authorized generic contributing $249.1 million and newly launched Lifyorli delivering $91.4 million (92% sequential growth). Net income surged to $126.8 million from $19.7 million in the prior year period. Cash position reached $662 million. ADA and AACE endorsements of CATALYST findings are expected to expand hypercortisolism diagnosis and treatment.
Guidance
Management reiterated 2026 full-year revenue guidance of $1.1B-$1.2B. Long-term targets include Cushing's syndrome business reaching at least $2B annually by decade-end, with relacorilant launch potentially driving $3B-$5B in revenue by 2030.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 3, 2026$1.01
est $0.79
+27.2%$340.5M
est $336.4M
+1.2%−1.5%
Jul 29, 2026$0.36
est −$0.04
+1,000.0%$256.1M
est $221.1M
+15.8%+25.6%
Apr 30, 2026−$0.30
est −$0.14
−114.3%$164.9M
est $185.3M
−11.0%+10.4%
Feb 24, 2026$0.20
est $0.25
−21.3%$202.1M
est $254.9M
−20.7%+2.5%
Nov 4, 2025$0.16
est $0.18
−11.1%$207.6M
est $255.3M
−18.7%+3.3%
Jul 31, 2025$0.29
est $0.19
+52.6%$194.4M
est $244.6M
−20.5%−1.3%
May 5, 2025$0.17
est $0.14
+21.4%$157.2M
est $216.7M
−27.4%−2.8%
Feb 26, 2025$0.26
est $0.42
−38.6%$181.9M
est $200.1M
−9.1%−2.3%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Corcept Therapeutics stock forecast and analyst price targets

Analysts’ average 12-month price target for Corcept Therapeutics is $142.60, +95.5% from the last close, from 4 firms rating the stock in the last 90 days.

$142.60consensus 12-month target, +95.5% from the last close
Low $161High $173
Buy4
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 4 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 5H.C. WainwrightBuy, maintained$165+126.2%
Nov 5Canaccord GenuityBuy, reiterated$161+120.7%
Nov 4Piper SandlerBuy, reiterated$173+137.2%
Nov 2H.C. WainwrightBuy, maintained$165+126.2%
Oct 26Piper SandlerBuy, reiterated$165+126.2%
+11.7%average 20-day move after past Accumulation readings
−0.4%average move over the next 20 trading days in the last 5 years
±6.4%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Corcept Therapeutics seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Corcept Therapeutics averaged −0.4% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−16.5%2021−19.2%2022+18.2%2023+1.1%2024+15.6%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+0.9%3 of 5
Next 10 trading days+0.1%3 of 5
Next 15 trading days+1.2%3 of 5
Next 20 trading days−0.4%2 of 5
Next 30 trading days−4.7%1 of 5

For scale, CORT’s typical 20-trading-day move in either direction is about 10.1%.

Corcept Therapeutics market cap and key statistics

Corcept Therapeutics’s market cap is $7.98B, with a P/E ratio of 55.4 and revenue of $963.6M over the last twelve months.

Valuation

Market cap
$7.98B
P/E ratio
55.4
Forward P/E
15.2
EPS, TTM
$1.33
Gekko Fair Value
$97.61

Trading

Volume
1.11M
Avg volume, 20 days
1.30M
52-week high
$126.38
52-week low
$28.66
Shares outstanding
109.4M

Financials

Revenue, TTM
$963.6M
Profit margin
16.8%
Return on equity
22.2%
Quarterly earnings growth, YoY
+531.0%

Risk and income

Beta
0.56
Typical daily move
±6.4%
Typical 20-day move
±10.1%

Corcept Therapeutics peers

Corcept Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Corcept Therapeutics stock FAQ

What is Corcept Therapeutics’s market cap?

Corcept Therapeutics’s market cap is $7.98B at the Nov 13, 2026 close of $72.94, with 109.4M shares outstanding. The shares trade on a P/E ratio of 55.4.

What is the Corcept Therapeutics stock forecast?

The consensus analyst 12-month price target for Corcept Therapeutics is $142.60, +95.5% from the last close. Of the 4 firms that rated the stock in the last 90 days, 4 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Corcept Therapeutics stock overvalued or undervalued?

On Gekko’s estimate Corcept Therapeutics is undervalued: the Nov 13, 2026 close of $72.94 is 25.3% below Gekko Fair Value of $97.61. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Corcept Therapeutics report earnings next?

Corcept Therapeutics is expected to report on Feb 23, 2027, after the market closes (100 days away). Analysts expect earnings of $1.12 per share on revenue of $396.6M. Corcept Therapeutics beat the earnings estimate in 4 of its last 8 reports, moving 6.2% on average across the report.

What is Corcept Therapeutics’s 52-week high and low?

Corcept Therapeutics’s 52-week high is $126.38 and its 52-week low is $28.66; it closed at $72.94 on Nov 13, 2026, −7.0% over the past year.

Is Corcept Therapeutics stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Corcept Therapeutics the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.